Paris-Trousseau thrombopenia
Paris-Trousseau thrombopenia is a rare genetic disorder characterized by a reduction in the number of platelets in the blood, a condition known as thrombocytopenia. This disorder is part of a group of diseases that affect platelet function and number, leading to a predisposition to bleeding. Paris-Trousseau thrombopenia is distinguished by its genetic cause and specific clinical features, including abnormal bleeding and the presence of giant alpha-granules in megakaryocytes (the bone marrow cells responsible for the production of platelets).
Causes[edit | edit source]
Paris-Trousseau thrombopenia is caused by genetic mutations that affect the production or function of platelets. The disorder is often associated with deletions or mutations in the FLI1 gene, which plays a crucial role in the development and function of megakaryocytes and platelets. The FLI1 gene is located on chromosome 11 and is essential for the proper formation of blood cells.
Symptoms[edit | edit source]
Individuals with Paris-Trousseau thrombopenia typically present with symptoms related to abnormal bleeding. These can include:
- Easy bruising
- Prolonged bleeding from minor wounds
- Bleeding gums
- Nosebleeds
- Heavy menstrual bleeding in women
In addition to these symptoms, patients may also have distinctive features on their blood tests, such as the presence of giant alpha-granules in megakaryocytes, seen under a microscope.
Diagnosis[edit | edit source]
The diagnosis of Paris-Trousseau thrombopenia is based on clinical evaluation, family history, and specialized blood tests. A complete blood count (CBC) may show a reduced number of platelets. Further diagnostic tests, including bone marrow biopsy and genetic testing, can help confirm the diagnosis by identifying the characteristic giant alpha-granules in megakaryocytes and the specific genetic mutation associated with the disorder.
Treatment[edit | edit source]
There is no cure for Paris-Trousseau thrombopenia, and treatment focuses on managing symptoms and preventing bleeding complications. Treatment strategies may include:
- Platelet transfusions for severe bleeding episodes
- Use of antifibrinolytic agents to prevent bleeding
- Hormonal treatments to reduce menstrual bleeding in women
Patients with Paris-Trousseau thrombopenia should also be advised to avoid medications that can further reduce platelet function, such as aspirin and certain non-steroidal anti-inflammatory drugs (NSAIDs).
Prognosis[edit | edit source]
The prognosis for individuals with Paris-Trousseau thrombopenia varies. Some individuals may have mild symptoms and lead normal lives, while others may experience more severe bleeding complications. Regular follow-up with a healthcare provider specializing in blood disorders is essential to manage the condition effectively.
Paris-Trousseau thrombopenia Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD